Outcomes with first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) vs physician's choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2-advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial

Sadeleştirilmiş öğe sayfası
dc.contributor.authorEl Saghir, Nagi S.
dc.contributor.authorYap, Yoon Sim
dc.contributor.authorEralp, Yesim
dc.contributor.authorIm, Seock\\-Ah
dc.contributor.authorAzim, Hamdy A.
dc.contributor.authorRihani, Julie
dc.contributor.authorVolkov, Nikita
dc.contributor.authorChen, Shin\\-Cheh
dc.contributor.authorHarputluoglu, Hakan
dc.contributor.authorSunpaweravong, Patrapim
dc.contributor.authorChang, Yuan\\-Ching
dc.contributor.authorDelgar Alfaro, Teresa
dc.contributor.authorWu, Jiwen
dc.contributor.authorHu, Huilin
dc.contributor.authorGao, Ming
dc.contributor.authorLu, Yen\\-Shen
dc.date.accessioned2025-10-16T15:15:20Z
dc.date.issued2023
dc.identifier.doi10.1200/JCO.2023.41.16\_suppl.1063
dc.identifier.otherWOS:001555395200010
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/6417
dc.publisherLIPPINCOTT WILLIAMS \& WILKINS
dc.sourceJOURNAL OF CLINICAL ONCOLOGY
dc.titleOutcomes with first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) vs physician's choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2-advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial
dc.typeMeeting Abstract

Dosyalar

Koleksiyonlar

WOS